Shanghai, January 11, 2016-- WuXi AppTec announced to start construction of the World * * Integrated Biomedical R&D Service Center in the company's Shanghai headquarters park, aiming to provide integrated solutions for global biopharmaceutical discovery, development and clinical production, and provide one-stop services for promoting biopharmaceutical R&D from innovative ideas to clinical applications. The center project plans to invest a total of 120 million dollars and cover an area of 250000 square feet. After completion, it can accommodate 800 scientists. The new center is expected to be completed and put into use in 2017.
WuXi AppTec Biomedical R&D Service Center consists of the Biomedical Discovery Center, the Development Center and the cGMP clinical sample base. The Biological Drug Discovery Center will cooperate with the American OMT (Open Monoclonal Technology), through OMT's advanced human monoclonal antibody platform OmniRat ™ And WuXi AppTec's proprietary phage display library to help customers around the world develop conventional monoclonal antibodies, bispecific monoclonal antibodies and antibody coupling drugs. Biopharmaceutical Development Center adopts WuXi AppTec's CHO with independent intellectual property rights Cell line platform, its advanced feeding and perfusion process can meet various rigorous process requirements. cGMP The clinical sample base will be equipped with three 2000 liter fed bioreactors and two 500 liter fed bioreactors, which can simultaneously prepare four kinds of clinical samples. By integrating the needs of biopharmaceutical discovery, development and sample preparation, the new R&D service center will provide more high-quality, efficient, fast and flexible services for the innovative biopharmaceutical R&D of WuXi AppTec's global customers.
"WuXi AppTec's continuous investment in biological drug R&D capacity will better support the rapidly growing R&D business needs of our global customers," said Dr. Li Ge, chairman and executive officer of WuXi AppTec, "The completion of the new center will further strengthen WuXi AppTec's * * position in the global biopharmaceutical R&D service field, and provide * * *, integrated and innovative R&D solutions for the company's global customers."
(Reprinted/Internet information)
